This week the University of Cambridge announce the appointment of Dr Diarmuid O'Brien, current Chief Executive of Cambridge Enterprise, as their new Pro-Vice-Chancellor of Innovation.  Click here to read the full story.

London, UK - Award-winning science communications agency First Create The Media is delighted to announce the appointment of Dr Sarah Hazell as its new Chief Executive Officer. Founded in 2018 by renowned science writer and broadcaster Dr Kat Arney, First Create The Media has quickly become a prominent player in the life sciences sector. The agency brings together a team of experts with decades of experience to provide strategic communications consultancy and high quality written, audio and video content for innovative companies and the ecosystem that supports them. First Create The Media…

London, 24 January 2024 – Kadans Science Partner (“Kadans”) has received planning approval from Cambridge City Council for the development of a new, purpose-built laboratory and office building at Merlin Place, Cambridge, a new Gateway Building for the Cambridge North Cluster. The six-storey 139,000 sq ft building allows for full flexibility from a single to multi tenant split. The design includes south-facing balconies benefiting from unrivalled views to the historic city centre along with significant communal space and a much-needed additional public café to the Cambridge North Cluster with…

Arecor Therapeutics plc (“Arecor” or the “Company”) ARECOR ANNOUNCES UPDATE ON INBRX-101 - Sanofi to acquire Inhibrx’s AATD therapy INBRX-101, which incorporates a novel formulation developed under a license agreement using Arecor’s Arestat™ technology, for up to $2.2 billion - Terms of Arecor’s license agreement are unchanged. Arecor remains entitled to further payments on achievement of certain development, regulatory and commercial milestones along with annual Technology Access Fees post commercialisation Cambridge, UK, 23 January 2024: Arecor Therapeutics plc (AIM: AREC), the…

Arecor Therapeutics plc (“Arecor” or the “Group”) ARECOR GRANTED KEY EUROPEAN PATENT EXTENDING PROTECTION FOR INSULIN PRODUCTS, AT278 AND AT247 Cambridge, UK, 18 January 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce that the European Patent Office has granted a patent (EP3618840) protecting novel formulations of the Group’s proprietary insulin products, AT278 and AT247. The European patent adds to a comprehensive global intellectual property (IP) portfolio protecting the Group’s novel…

Apply now to participate in the next Pioneer Accelerator Programme designed to help businesses launch, grow and scale.  Available programmes include:  Pioneer Group Accelerator Programme, Ireland Health Innovation East Midlands NHS Programme Pioneer Group Accelerator Programme, England & Wales Pioneer Group Accelerator Programme, Scotland    For more information, please visit: https://thepioneergroup.com/accelerator-programme/

AMSBIO has launched a new 2024 travel grant award scheme for scientists under the age of thirty, employed in academia, research institutions, or companies engaged in cancer and stem cell research. Working closely with the global life science community for over three decades AMSBIO believes in partnership and paying back by supporting new research and researchers. Last year, the company funded a travel grant to attend ISSCR 2023. It was so popular that this year AMSBIO are offering two grant schemes: one for the AACR Annual Meeting 2024 in San Diego, USA, and another for the ISSCR Annual…

Strategic partnership harnesses respective organ-specific expertise to provide complete human-derived Organ-on-a-Chip solution for more accurate in vitro ADME predictions   Early access to dual-organ model available through CN Bio’s Contract Research Services    Cambridge, UK, and Durham, North Carolina, US, 23 January 2024: CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership. Through this partnership, Altis’ human RepliGut®…

In the first People Pathways edition of the year, we are thrilled to bring you our 4th annual Building Life Sciences Adventures (BLSA) Conference and wanted to share a glimpse of the exiting journey that lies ahead. Click here to read about:✳ Top 5 reasons why you should sponsor BLSA...✳ New funding for employers to support with offering industry placements...✳ Upcoming training and events...

Excitement is in the air as we approach our Annual Awards Dinner on 21 March 2024, at stunning London venue, No.11 Cavendish Square.  Get your nominations in and be part of an evening that recognises and celebrates the success of our community. Remember, you have the opportunity to nominate either your own company or a company you've worked with to acknowledge their exceptional performance. Entries close on 7 February. Catergories Primary R&D Company - Sponsored by BMG LABTECH Investor Provider Technology Transfer Office Professional Services Company Facilities Provider Non-…